The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2016 | Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC
Rosalyn Juergens, MD, PhD of McMaster University, Juravinski Cancer Centre, Canada talks about the Canadian Clinical Trials Group’s (CCTG) next randomized Phase II trial of double immunotherapy with durvalumab and tremelimumab versus quadruple therapy with durvalumab, tremelimumab, and platinum doublet chemotherapy (NCT03057106). Recorded at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.
